Jazz Fibromyalgia Candidate Needs More Risk Management, Advisory Panel Tells FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Members side with the agency against a new name and a separate Risk Evaluation and Mitigation Strategy for the new indication.
You may also be interested in...
Confluence of Symptoms and Treatments at FDA Patient Meetings
The first round of four PDUFA patient-focused meetings concluded with the Sept. 24 meeting on narcolepsy. FDA is beginning to look ahead to the fiscal 2014 meetings – to start with fibromyalgia on December 10. One pattern that is emerging is that three of the first five conditions discussed with patients have overlapping symptoms and treatments.
Narrower Indication, New Studies Are Likely Riffs For Jazz Fibromyalgia Drug
Jazz Pharmaceuticals will likely have to narrow the proposed indication for its fibromyalgia drug JZP-6 (sodium oxybate) following a "complete response" letter from FDA, but that appears to be only the first step for the product.
Narrower Indication, New Studies Are Likely Riffs For Jazz Fibromyalgia Drug
Jazz Pharmaceuticals will likely have to narrow the proposed indication for its fibromyalgia drug JZP-6 (sodium oxybate) following a "complete response" letter from FDA, but that appears to be only the first step for the product.